{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:15:18Z","timestamp":1758046518282,"version":"3.44.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.pharma.2009.05.006","type":"journal-article","created":{"date-parts":[[2009,7,30]],"date-time":"2009-07-30T10:32:12Z","timestamp":1248949932000},"page":"369-373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Traitements de substitution aux opiac\u00e9s\u00a0: \u00e9tat des lieux du point de vue du m\u00e9decin"],"prefix":"10.1016","volume":"67","author":[{"given":"L.","family":"Michel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2009.05.006_bib1","unstructured":"Strat\u00e9gies th\u00e9rapeutiques pour les personnes d\u00e9pendantes des opiac\u00e9s\u00a0: place des traitements de substitution. In\u00a0: Conf\u00e9rence de consensus \u2013 F\u00e9d\u00e9ration fran\u00e7aise d\u2019addictologie. 2004. Lyon, 23\u201324\u00a0juin 2004\u00a0: alcoologie et addictologie."},{"issue":"11","key":"10.1016\/j.pharma.2009.05.006_bib2","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/j.1360-0443.2005.01271.x","article-title":"Harm reduction interventions, behaviours and associated health outcomes in France, 1996\u20132003","volume":"100","author":"Emmanuelli","year":"2005","journal-title":"Addiction"},{"key":"10.1016\/j.pharma.2009.05.006_bib3","unstructured":"OFDT, Estimation du nombre de personnes recevant un traitement de substitution (subutex 8mg, m\u00e9thadone 60mg) depuis 1995. OFDT 2008."},{"issue":"9","key":"10.1016\/j.pharma.2009.05.006_bib4","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1360-0443.2007.01912.x","article-title":"Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users","volume":"102","author":"Van Den Berg","year":"2007","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.pharma.2009.05.006_bib5","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/jat\/22.6.430","article-title":"Buprenorphine-related deaths among drug addicts in France: a report on 20\u00a0fatalities","volume":"22","author":"Tracqui","year":"1998","journal-title":"J Anal Toxicol"},{"issue":"2","key":"10.1016\/j.pharma.2009.05.006_bib6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1360-0443.2001.96226710.x","article-title":"Injecting misuse of buprenorphine among French drug users","volume":"96","author":"Obadia","year":"2001","journal-title":"Addiction"},{"issue":"S4","key":"10.1016\/j.pharma.2009.05.006_bib7","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1086\/508184","article-title":"Buprenorphine use: the international experience","volume":"43","author":"Carrieri","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.pharma.2009.05.006_bib8","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1111\/j.1360-0443.2008.02323.x","article-title":"The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000\u00a0cohort study","volume":"103","author":"Roux","year":"2008","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.pharma.2009.05.006_bib9","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1360-0443.2004.00821.x","article-title":"Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?","volume":"99","author":"Schaefer","year":"2004","journal-title":"Addiction"},{"issue":"S1","key":"10.1016\/j.pharma.2009.05.006_bib10","article-title":"Health related quality of life among HIV-HCV co-infected patients","volume":"54","author":"Pr\u00e9au","year":"2006","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"S18","key":"10.1016\/j.pharma.2009.05.006_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0755-4982(04)72376-3","article-title":"The profile of drug addicts attending the Sainte Marguerite University Hospital in Marseille analysis of the active file from 1996 to 2001","volume":"33","author":"Lan\u00e7on","year":"2004","journal-title":"Presse Med"},{"issue":"1 Pt 1","key":"10.1016\/j.pharma.2009.05.006_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gcb.2008.11.009","article-title":"French prospective observational study of the treatment of chronic hepatitis C in drug abusers: a commentary","volume":"33","author":"Michel","year":"2009","journal-title":"Gastroenterol Clin Biol"},{"year":"1999","series-title":"Usages de drogue et comorbidit\u00e9s psychiatriques\u00a0: synth\u00e8se des recherches am\u00e9ricaines","author":"Barrow","key":"10.1016\/j.pharma.2009.05.006_bib13"},{"issue":"2","key":"10.1016\/j.pharma.2009.05.006_bib14","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependenc","author":"Mattick","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharma.2009.05.006_bib15","unstructured":"WHO, Substitution maintenance therapy in the management of opioid dependence and HIV\/AIDS prevention. In: WHO\/UNODC\/UNAIDS position paper 2004:Geneva."},{"issue":"1\u20133","key":"10.1016\/j.pharma.2009.05.006_bib16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.drugalcdep.2008.07.007","article-title":"Withdrawal symptoms as a predictor of mortality in patients HIV-infected through drug use and receiving highly active antiretroviral therapy (HAART)","volume":"99","author":"Michel","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pharma.2009.05.006_bib17","doi-asserted-by":"crossref","unstructured":"Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003;(3):CD002208.","DOI":"10.1002\/14651858.CD002208"},{"key":"10.1016\/j.pharma.2009.05.006_bib18","unstructured":"Afssaps. \u00c9valuation et prise en charge des troubles psychiatriques chez les patients adultes infect\u00e9s par le virus de l\u2019h\u00e9patite C et trait\u00e9s par (peg) interf\u00e9ron alfa et ribavirine. Le courrier des addictions 2008;10(2):9\u201312."}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450909000844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450909000844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:27:31Z","timestamp":1757719651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450909000844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0003450909000844"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2009.05.006","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2009,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traitements de substitution aux opiac\u00e9s\u00a0: \u00e9tat des lieux du point de vue du m\u00e9decin","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2009.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}